Omacetaxine: Clinical Trials

9 trials of Omacetaxine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 6 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 3, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 25Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Omacetaxine: new trials by email Literature Review of Omacetaxine trials Research Report on Omacetaxine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)
Omacetaxine, Venetoclax - Relapsed or Refractory Hematologic Malignancies
Phase 1CompletedUniversity of Illinois at Chicago62022-06-212026-03-16
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
Omacetaxine, Azacitidine - High Grade Myelodysplastic Syndromes
Phase 1 / Phase 2Active not recruitingUniversity of Colorado, Denver292018-09-172026-11-06
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
Omacetaxine, Azacitidine, G-CSF - Myelodysplastic Syndromes
Phase 1 / Phase 2WithdrawnUniversity of Florida2016-08-012017-05-03
Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
Omacetaxine - Leukemia
Phase 2CompletedM.D. Anderson Cancer Center482015-05-182021-06-09
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Omacetaxine, Decitabine - Leukemia
Phase 1TerminatedM.D. Anderson Cancer Center22015-05-062018-02-13
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
omacetaxine mepesuccinate - Hematologic Malignancies, Solid Tumors
Phase 1CompletedTeva Branded Pharmaceutical Products R&D, Inc.62013-07-012015-01-30
Omacetaxine for Consolidation and Maintenance
Omacetaxine - Acute Myelogenous Leukemia (AML)
Phase 2TerminatedEmory University72013-05-012019-09-24
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Omacetaxine, Cytarabine - Leukemia
Phase 2CompletedM.D. Anderson Cancer Center362011-07-012018-05-30
Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
Omacetaxine - Hematologic Tumors
Phase 1CompletedChemGenex Pharmaceuticals122008-04-012014-05-12

Conditions studied

Leukemia (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Hematologic Neoplasms (2)  ·  Myelodysplastic Syndromes (2)  ·  Recurrence (1)

Sponsors

M.D. Anderson Cancer Center (3)  ·  ChemGenex Pharmaceuticals (1)  ·  Emory University (1)  ·  Teva Branded Pharmaceutical Products R&D, Inc. (1)  ·  University of Colorado, Denver (1)  ·  University of Florida (1)  ·  University of Illinois at Chicago (1)

Countries

United States (8)  ·  Netherlands (1)

Top investigators

Elias Jabbour, MD (2)  ·  Daniel Pollyea, MD (1)  ·  Hagop Kantarjian, MD (1)  ·  John Nemunaitis, M.D. (1)  ·  John Quigley, MD (1)  ·  Martha L. Arellano, MD (1)  ·  Maxim N. Norkin, MD, PhD (1)

Results publications

PMID 41140451